1. Home
  2. WOLF vs VIR Comparison

WOLF vs VIR Comparison

Compare WOLF & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wolfspeed Inc.

WOLF

Wolfspeed Inc.

HOLD

Current Price

$18.45

Market Cap

838.3M

Sector

Technology

ML Signal

HOLD

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

HOLD

Current Price

$5.75

Market Cap

773.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WOLF
VIR
Founded
1987
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
838.3M
773.5M
IPO Year
1993
2019

Fundamental Metrics

Financial Performance
Metric
WOLF
VIR
Price
$18.45
$5.75
Analyst Decision
Hold
Strong Buy
Analyst Count
7
11
Target Price
$10.50
$25.73
AVG Volume (30 Days)
1.4M
2.0M
Earning Date
01-28-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$759,700,000.00
$16,860,000.00
Revenue This Year
$14.86
N/A
Revenue Next Year
N/A
$48.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.05
$4.16
52 Week High
$36.60
$14.45

Technical Indicators

Market Signals
Indicator
WOLF
VIR
Relative Strength Index (RSI) 43.60 42.12
Support Level $17.02 $6.49
Resistance Level $18.49 $6.75
Average True Range (ATR) 1.37 0.48
MACD -0.29 -0.09
Stochastic Oscillator 21.77 18.63

Price Performance

Historical Comparison
WOLF
VIR

About WOLF Wolfspeed Inc.

Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Share on Social Networks: